Does Cosentyx Affect COVID-19 Vaccine Response?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, suppresses parts of the immune system. This can reduce vaccine effectiveness, including for COVID-19 mRNA vaccines like Pfizer or Moderna. Studies show biologic users, including those on IL-17 inhibitors, mount weaker antibody responses post-vaccination compared to healthy individuals.[1][2]
Recommended Timing for Vaccination
No specific contraindications exist for Cosentyx users receiving COVID-19 vaccines—major health bodies like CDC, EMA, and ACR endorse vaccination. Get vaccinated even if on Cosentyx; boosters help overcome reduced response. Schedule doses between Cosentyx injections if possible, but data doesn't show harm from concurrent timing.[3][4]
What If You've Recently Started or Adjusted Cosentyx?
Hold Cosentyx for 1-2 weeks before and after vaccination only if infection risk is high (e.g., during Delta/Omicron peaks), per some rheumatologist guidance. This isn't standard; resuming promptly maintains disease control. Live-attenuated COVID vaccines aren't used, so no live-virus precautions apply.[5]
Monitoring After Vaccination
Watch for infection signs post-vaccine, as immunosuppression raises breakthrough COVID risk. Report persistent fever, cough, or worsening symptoms to your doctor. Cosentyx doesn't increase vaccine side effects like myocarditis or anaphylaxis beyond general population rates.[1][6]
Comparing with Other Biologics
| Biologic Class | COVID Vaccine Response Impact | Key Difference from Cosentyx |
|---------------|-------------------------------|------------------------------|
| TNF inhibitors (e.g., Humira) | Moderate antibody reduction | Similar to Cosentyx; no hold recommended |
| IL-6 inhibitors (e.g., Olumiant) | Stronger T-cell response preservation | Better cellular immunity than IL-17 blockers |
| JAK inhibitors (e.g., Xeljanz) | Variable; some hold advised | Higher thrombosis risk post-vaccine in trials |
Cosentyx users fare similarly to other biologics but may need serologic testing to confirm immunity.[2][7]
Patient Reports and Real-World Data
Autoimmune patients on Cosentyx report standard vaccine side effects (fatigue, arm pain) but higher breakthrough rates in registries like CORONA. Rheumatology societies advise against routine pausing therapy unless severely immunocompromised.[4][8]
[1]: CDC: COVID-19 Vaccines for Immunocompromised
[2]: Annals of Rheumatic Diseases: Vaccine Response in IL-17 Inhibitors
[3]: ACR: COVID-19 Vaccine Guidance
[4]: EMA: Secukinumab SmPC
[5]: EULAR: Vaccination in Rheumatic Diseases
[6]: Novartis Cosentyx Prescribing Info
[7]: Rheumatology: Biologics Comparison Study
[8]: COVID Global Rheumatology Alliance Registry